Open Access
| Issue |
Med Sci (Paris)
Volume 40, Number 8-9, Août-Septembre 2024
Chroniques génomiques
|
|
|---|---|---|
| Page(s) | 677 - 679 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/2024093 | |
| Published online | 20 September 2024 | |
- Chneiweiss H. 2023 : premiers succès et nouveaux enjeux de l’édition du génome en thérapeutique humaine. Med Sci (Paris) 2023 ; 39 : 589–90. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Jordan B. Édition de gènes in vivo et thérapie génique Med Sci (Paris) 2021 ; 37 : 933–5. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Bernstein JA. Severity of hereditary angioedema, prevalence, and diagnostic considerations. Am J Manag Care 2018 ; 24 : S292–8. [PubMed] [Google Scholar]
- Ebo DG, Bridts CH. Images in clinical medicine. Disfiguring angioedema. N Engl J Med 2012 ; 367 : 1539. [CrossRef] [PubMed] [Google Scholar]
- Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010 ; 363 : 513–22. [CrossRef] [PubMed] [Google Scholar]
- Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA 2018 ; 20 : 2108–21. [CrossRef] [PubMed] [Google Scholar]
- Fijen LM, Riedl MA, Bordone L, et al. Inhibition of Prekallikrein for Hereditary Angioedema. N Engl J Med 2022 ; 386 : 1026–33. [CrossRef] [PubMed] [Google Scholar]
- Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med 2021 ; 385 : 493–502. [CrossRef] [PubMed] [Google Scholar]
- Longhurst HJ, Lindsay K, Petersen RS, et al. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med 2024 ; 390 : 432–41. [CrossRef] [PubMed] [Google Scholar]
- Barco S, Sollfrank S, Trinchero A, et al. Severe plasma prekallikrein deficiency: clinical characteristics, novel KLKB1 mutations, and estimated prevalence. J Thromb Haemost 2020 ; 18 : 1598–617. [CrossRef] [PubMed] [Google Scholar]
- Henderson ML, Zieba JK, Li X, et al. Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care. BioTech (Basel) 2024 ; 13 : 1. [CrossRef] [Google Scholar]
- Pierce EA, Aleman TS, Jayasundera KT, et al. Gene Editing for CEP290-Associated Retinal Degeneration. N Engl J Med 2024. doi: 10.1056/NEJMoa2309915. [PubMed] [Google Scholar]
- Henry B. Drug Pricing & Challenges To Hepatitis C Treatment Access. J Health Biomed Law 2018 : 14 : 265–83. [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.